Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,017 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Systemic Infection Clear all

Conditions: Sepsis
Interventions: Drotrecogin alfa (activated), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 23
States / cities: Birmingham, Alabama • Loma Linda, California • Long Beach, California + 20 more

Conditions: Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: darbepoetin alfa, epoetin alfa, fatigue assessment and management, quality-of-life assessment; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
Interventions: Valganciclovir, Ganciclovir (GCV), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Onychomycosis
Interventions: ME1111 solution, Vehicle Solution; Drug
Lead sponsor: Meiji Seika Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 2
States / cities: Austin, Texas • College Station, Texas

Conditions: Sepsis
Interventions: Implementation and evaluation of a sepsis sub-phenotyping algorithm; Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 1,916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Cancer, Heart Failure, COPD, Sepsis, HIV Infections, ESRD, Trauma, Stroke
Interventions: Therapeutic massage; Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Graft-Versus-Host Disease (cGVHD)
Interventions: Vimseltinib; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Duarte, California • Los Angeles, California • Orange, California + 22 more

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome
Interventions: GM-CSF, Placebo; Drug · Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 21 more

Conditions: Acute Myeloid Leukemia
Interventions: Planned Chemotherapy; Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bacterial Sepsis
Interventions: low-carbohydrate nutrition, Standard enteral nutrition; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Infection, Bacteremia
Interventions: Telavancin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Sepsis
Interventions: No Intervention: Observational Cohort; Other
Lead sponsor: University of British Columbia; Other
Eligibility: 5 Years to 16 Years
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: San Francisco, California • Ithaca, New York • Seattle, Washington

Conditions: Lupus Nephritis, Systemic Lupus Erythematosus
Interventions: ATA3219; Drug
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Thousand Oaks, California

Conditions: Septic Shock
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
Interventions: Angiotensin II and hydrocortisone sodium succinate; Drug
Lead sponsor: Kingman Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kingman, Arizona

Conditions: Sepsis, Shock, Septic, Sepsis Syndrome, Septicemia, Infection
Interventions: E5564; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 17
States / cities: Mobile, Alabama • San Diego, California • Santa Barbara, California + 14 more

Conditions: Sepsis
Interventions: Treatment of Sepsis; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Botulism, Iatrogenic Botulism
Interventions: Amifampridine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Pediatric ALL, Sepsis
Interventions: Pediatric eCART; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 17 Years
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Gram-negative Bacteremia
Interventions: Intravenous Antibiotics, Oral Antibiotics; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more

Conditions: Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions: Exenatide, Exenatide vehicle; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Kidney Injury, Acute Kidney Injury Due to Sepsis, Neonatal Sepsis
Interventions: Renal Angina Index (RAI); Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Kidney Injury Due to Sepsis
Interventions: TIN816 70 mg lyophilisate powder, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 14 more

Search by objective public record fields.

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients

Novel Sepsis Sub-phenotypes Based on Trajectories of Vital Signs

Study to Determine Therapeutic Massage Dosing to Improve Quality of Life in Hospitalized Patients Receiving Palliative Care

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy

Study of Low Carbohydrate Enteral Nutrition in Patients With Bacterial Septic Shock

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)

Smart Discharges for Older Children

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

Change in MAPSE During Treatment of Sepsis

Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA

Evaluation of Pediatric eCART Implementation

Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial

Pharmacology of Exenatide in Pediatric Sepsis

Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric and Neonatal AKI

Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)